PBGENE HBV

iECURE's ECUR-506, an in vivo gene insertion therapy, demonstrated a complete clinical response in an infant with neonatal-onset Ornithine Transcarbamylase (OTC) deficiency.

Precision BioSciences' PBGENE-HBV demonstrated a favorable safety profile in initial Phase 1 trial results, with no serious adverse events reported in the first cohort.

Precision BioSciences received approval in Moldova for a clinical trial of PBGENE-HBV, an in vivo gene editing therapy targeting chronic hepatitis B.

Precision BioSciences received approval for its Clinical Trial Application for PBGENE-HBV, a gene editing therapy for chronic hepatitis B.

Precision BioSciences has received CTA approval in Moldova to begin a Phase 1 clinical trial of PBGENE-HBV, a gene editing therapy for chronic hepatitis B.